{"transactions":[{"id":890429,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-02-20T16:16:27.000Z","date":"2026-02-19","kind":"grant","planned":false,"acquired":true,"shares":85000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 19, 2026. The 85,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer."}],"balance_after":85000,"derivative":{"exercise_price":10.56,"expiration_date":"2036-02-18","underlying":"Common Stock","underlying_shares":85000},"source":{"system":"sec-edgar","filing":"0001193125-26-061394","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000119312526061394/ownership.xml","form_type":"4"}},{"id":1124543,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-06-03T16:00:37.000Z","date":"2025-05-31","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 60,000 shares of common stock."}],"balance_after":92000,"derivative":{"exercise_price":2.38,"exercise_date":"2025-05-31","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-080887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025080887/ownership.xml","form_type":"4"}},{"id":1190738,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"exercise","planned":false,"acquired":false,"shares":2631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 15, 2015. The 2,631 shares of common stock underlying the option vested as to 25% of the shares on May 15, 2016 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through May 15, 2019."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2025-05-14","underlying":"Common Stock","underlying_shares":2631},"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1190737,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"sale","planned":false,"acquired":false,"shares":2631,"price":6.6,"value":17364.6,"ownership":{"direct":true},"balance_after":221373,"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1190736,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-26T16:30:14.000Z","date":"2025-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2631,"price":1.43,"value":3762.33,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,058 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":224004,"source":{"system":"sec-edgar","filing":"0000950170-25-045295","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025045295/ownership.xml","form_type":"4"}},{"id":1209391,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Performance Stock Option (right to buy)","published_at":"2025-03-12T16:00:07.000Z","date":"2025-03-10","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 100,000 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 32,000 shares of common stock. The performance-based stock option remains eligible for vesting with respect to additional shares of common stock underlying the option in the event that performance metrics related to the successful results of the CORAL trial are satisfied."}],"balance_after":32000,"derivative":{"exercise_price":2.38,"exercise_date":"2025-03-10","expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-25-037883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025037883/ownership.xml","form_type":"4"}},{"id":1255329,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-20T16:00:14.000Z","date":"2025-02-18","kind":"grant","planned":false,"acquired":true,"shares":116000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 18, 2025. The 116,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029."}],"balance_after":116000,"derivative":{"exercise_price":4.22,"expiration_date":"2035-02-17","underlying":"Common Stock","underlying_shares":116000},"source":{"system":"sec-edgar","filing":"0000950170-25-024117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017025024117/ownership.xml","form_type":"4"}},{"id":1426399,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"exercise","planned":false,"acquired":false,"shares":16496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":0,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":16496},"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}},{"id":1426398,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"sale","planned":false,"acquired":false,"shares":16496,"price":2.9633,"value":48882.5968,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.9000 to $3.0020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":220315,"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}},{"id":1426397,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-21T16:00:02.000Z","date":"2024-08-19","kind":"exercise","planned":false,"acquired":true,"shares":16496,"price":1.43,"value":23589.28,"ownership":{"direct":true},"balance_after":236811,"source":{"system":"sec-edgar","filing":"0000950170-24-099481","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024099481/ownership.xml","form_type":"4"}},{"id":1431156,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":false,"shares":18660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":16496,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":18660},"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431155,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":false,"shares":12745,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":35156,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":12745},"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431154,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on November 25, 2014. The 48,001 shares of common stock underlying the option vested as to 25% of the shares on November 25, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through November 25, 2018."}],"balance_after":47901,"derivative":{"exercise_price":1.43,"expiration_date":"2024-11-24","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431153,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-16","kind":"sale","planned":false,"acquired":false,"shares":18660,"price":2.7567,"value":51440.022,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":220315,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431152,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-16","kind":"exercise","planned":false,"acquired":true,"shares":18660,"price":1.43,"value":26683.8,"ownership":{"direct":true},"balance_after":238975,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431151,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-15","kind":"sale","planned":false,"acquired":false,"shares":12745,"price":2.7864,"value":35512.668,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.8020 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":220315,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431150,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-15","kind":"exercise","planned":false,"acquired":true,"shares":12745,"price":1.43,"value":18225.35,"ownership":{"direct":true},"balance_after":233060,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431149,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":100,"price":2.75,"value":275.0,"ownership":{"direct":true},"balance_after":220315,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1431148,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-16T16:47:10.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":100,"price":1.43,"value":143.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 5,882 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":220415,"source":{"system":"sec-edgar","filing":"0000950170-24-098117","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024098117/ownership.xml","form_type":"4"}},{"id":1496442,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-05-31T16:07:36.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":false,"shares":59354,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on July 2, 2014. The 59,354 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018."}],"balance_after":0,"derivative":{"exercise_price":2.19,"expiration_date":"2024-07-01","underlying":"Common Stock","underlying_shares":59354},"source":{"system":"sec-edgar","filing":"0000950170-24-067305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024067305/ownership.xml","form_type":"4"}},{"id":1496441,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-31T16:07:36.000Z","date":"2024-05-29","kind":"sale","planned":false,"acquired":false,"shares":53368,"price":2.5504,"value":136109.7472,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale represents the sale of shares necessary to cover the cost of exercise and to meet tax withholding obligations as a result of the exercise of stock options on May 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 14,723 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":214433,"source":{"system":"sec-edgar","filing":"0000950170-24-067305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024067305/ownership.xml","form_type":"4"}},{"id":1496440,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-05-31T16:07:36.000Z","date":"2024-05-29","kind":"exercise","planned":false,"acquired":true,"shares":59354,"price":2.19,"value":129985.26,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 14,723 shares purchased through the Issuer's employee stock purchase plan."}],"balance_after":267801,"source":{"system":"sec-edgar","filing":"0000950170-24-067305","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024067305/ownership.xml","form_type":"4"}},{"id":1637916,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-16T16:42:38.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 15, 2024. The 150,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 15, 2025 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 15, 2028."}],"balance_after":150000,"derivative":{"exercise_price":2.38,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-24-016460","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000095017024016460/ownership.xml","form_type":"4"}},{"id":2010669,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-16T17:23:29.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2023. The 187,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027."}],"balance_after":187500,"derivative":{"exercise_price":2.67,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0001209191-23-010177","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000120919123010177/doc4.xml","form_type":"4"}},{"id":2155421,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Options (right to buy)","published_at":"2022-09-19T16:30:15.000Z","date":"2022-09-19","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On September 19, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that the performance metrics related to the successful results of the CANAL trial were satisfied, resulting in the vesting of the option as to the 7,500 shares of common stock."}],"balance_after":37500,"derivative":{"exercise_price":3.21,"exercise_date":"2022-09-19","expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-22-050525","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000120919122050525/doc4.xml","form_type":"4"}},{"id":2216940,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Options (right to buy)","published_at":"2022-07-01T16:51:25.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reporting person was granted a performance-based stock option on February 17, 2021, to purchase 37,500 shares of common stock. The option vests based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b/3 PRISM trial of Haduvio (nalbuphine ER) for the treatment of prurigo nodularis, and Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis. On June 29, 2022, the Compensation Committee of the Board of Directors of the Issuer certified that certain performance metrics related to the successful results of the PRISM trial were satisfied, resulting in the vesting of the option as to 30,000 shares of common stock. The performance-based option remains eligible for vesting with respect to the remaining shares of common stock underlying the option in the event that additional performance metrics related to the successful results of the CANAL trial are satisfied."}],"balance_after":30000,"derivative":{"exercise_price":3.21,"exercise_date":"2022-06-29","expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-040290","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000120919122040290/doc4.xml","form_type":"4"}},{"id":2216909,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-01T16:44:53.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"This amendment to the Form 4 originally filed for the reporting person on February 15, 2022 is being filed solely to attach the power of attorney exhibit that was inadvertently excluded from the original filing."}],"balance_after":110000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-22-040277","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000120919122040277/doc4a.xml","form_type":"4/A","original_submission_date":"2022-02-15"}},{"id":2394144,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-15T16:01:10.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 11, 2022. The 110,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 11, 2023 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026."}],"balance_after":110000,"derivative":{"exercise_price":0.511,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001209191-22-009743","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000120919122009743/doc4.xml","form_type":"4"}},{"id":2845785,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-19T16:15:36.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 17, 2021. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 17, 2022 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 17, 2025."}],"balance_after":50000,"derivative":{"exercise_price":3.21,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-21-007377","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924321007377/doc4.xml","form_type":"4"}},{"id":3266420,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-18T16:22:54.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 13, 2020. The 60,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024."}],"balance_after":60000,"derivative":{"exercise_price":5.5,"expiration_date":"2030-02-12","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899243-20-004877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924320004877/doc4.xml","form_type":"4"}},{"id":3500279,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-06-05T17:08:04.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2019. The 50,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on June 3, 2020 and as to the remaining 75% of the shares in equal monthly installments thereafter through June 3, 2023."}],"balance_after":50000,"derivative":{"exercise_price":10.12,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-015606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924319015606/doc4.xml","form_type":"4"}},{"id":3529542,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series C Preferred Stock","published_at":"2019-05-13T17:00:20.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":13410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1565},"source":{"system":"sec-edgar","filing":"0000899243-19-013248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924319013248/doc4.xml","form_type":"4"}},{"id":3529541,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Series A Preferred Stock","published_at":"2019-05-13T17:00:20.000Z","date":"2019-05-09","kind":"exercise","acquired":false,"shares":109015,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15553},"source":{"system":"sec-edgar","filing":"0000899243-19-013248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924319013248/doc4.xml","form_type":"4"}},{"id":3529540,"issuer":{"id":4387,"kind":"organization","name":"Trevi Therapeutics, Inc.","symbol":"TRVI"},"owners":[{"id":65403,"kind":"person","name":"SCIASCIA THOMAS","position":1,"cik":"0001229946","reported_name":"SCIASCIA THOMAS","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-05-13T17:00:20.000Z","date":"2019-05-09","kind":"exercise","acquired":true,"shares":17118,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 9, 2019, the Series A Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."}],"balance_after":193724,"source":{"system":"sec-edgar","filing":"0000899243-19-013248","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229946/000089924319013248/doc4.xml","form_type":"4"}}]}